欢迎访问《现代生物医学进展》编辑部！

目的：探究急性白血病患者给予沙利度胺配合化疗在抗血管生长方面的临床成效。方法：选取我院2009 年3 月-2014 年1 月收治的86 例急性白血病患者，随机分为研究组和对照组，每组43 例。对照组患者给予常规化疗方案，研究组在对照组基础上给予沙利度胺配合化疗。观察两组患者治疗前后血浆VEGF，VEGFR，bFGF及MVD 的水平变化。比较两组患者的临床疗效及不良反应发生率。结果：治疗前，两组患者VEGF、VEGFR、bFGF 及MVD 水平无显著差异（P>0.05）；治疗后，研究组患者VEGF、 VEGFR、bFGF及MVD 水平均低于对照组，差异有统计学意义（P<0.05）。研究组患者治疗的有效率为88.4 %，对照组为76.7 %，研究组显著优于对照组，差异具有统计学意义（P<0.05）。研究组不良反应发生率为79.1 %，对照组为81.4 %，差异无统计学意义（P>0.05）。结论：沙利度胺配合化疗治疗急性白血病能调控促血管生长因子水平，提高疗效，不良反应可耐受。

英文摘要:

Objective:To explore the clinical effect of thalidomide combined with chemotherapy in antiangiogenesis of acute leukemia patients.Methods:86 cases of acute leukemia were selected, who were treated in our hospital from March 2009 to January 2014 and randomly divided into the study group and the control group with 43 cases in each group. The patients in the control group received conventional chemotherapy, while the patients in the study group were given thalidomide combined with chemotherapy. Then the levels of VEGF, VEGFR, bFGF and MVD in plasma of patients were observed and compared before and after the treatment, and the clinical effect and the adverse reactions were compared between the two groups.Results:There was no statistically significant difference between the two groups about the VEGF, VEGFR, bFGF and MVD before treatment (P>0.05); the levels of VEGF, VEGFR, bFGF and MVD in the study group were lower than those of the control group after the treatment with statistically significant difference(P<0.05). The efficiency rate was 88.4 % in the study group which was higher than 76.7 % in the control group with statistical significance (P<0. 05). There was no statistically significant difference between the two groups in the adverse events (P>0.05).Conclusion:Thalidomide combined with chemotherapy compared with chemotherapy alone in acute leukemia, can regulate the angiogenic growth factor level, and the adverse reactions were acceptable.

查看全文查看/发表评论下载PDF阅读器

关闭